227 related articles for article (PubMed ID: 37477286)
1. Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients.
Fitzmaurice MG; Hohlfelder B; Srinivas P; Rudoni M; Brizendine KD; Budev M
Clin Transplant; 2023 Sep; 37(9):e15079. PubMed ID: 37477286
[TBL] [Abstract][Full Text] [Related]
2. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
Ganetsky A; Han JH; Hughes ME; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Luger SM; Mangan JK; Martin ME; Smith J; Freyer CW; Gilmar C; Schuster M; Stadtmauer EA; Porter DL
Clin Infect Dis; 2019 May; 68(12):2003-2009. PubMed ID: 30256954
[TBL] [Abstract][Full Text] [Related]
3. Oral vancomycin for Clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant.
Altemeier OJ; Konrardy KT
Transpl Infect Dis; 2022 Apr; 24(2):e13790. PubMed ID: 35014136
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
5. Oral vancomycin prophylaxis against recurrent
Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
[TBL] [Abstract][Full Text] [Related]
6. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
7. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
8. Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: A national propensity-score-adjusted retrospective cohort study.
Branch-Elliman W; Ripollone JE; O'Brien WJ; Itani KMF; Schweizer ML; Perencevich E; Strymish J; Gupta K
PLoS Med; 2017 Jul; 14(7):e1002340. PubMed ID: 28692690
[TBL] [Abstract][Full Text] [Related]
9. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients.
Schluger A; Rosenblatt R; Knotts R; Verna EC; Pereira MR
Transpl Infect Dis; 2019 Dec; 21(6):e13184. PubMed ID: 31571380
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients.
Splinter LE; Kerstenetzky L; Jorgenson MR; Descourouez JL; Leverson GE; Saddler CM; Smith JA; Safdar N; Redfield RR
Ann Pharmacother; 2018 Feb; 52(2):113-119. PubMed ID: 28844154
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
Knight EM; Schiller DS; Fulman MK; Rastogi R
J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
[TBL] [Abstract][Full Text] [Related]
12. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
[TBL] [Abstract][Full Text] [Related]
13. Oral Vancomycin as Secondary Prophylaxis for
Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients.
Neofytos D; Kobayashi K; Alonso CD; Cady-Reh J; Lepley D; Harris M; Desai N; Kraus E; Subramanian A; Treadway S; Ostrander D; Thompson C; Marr K
Transpl Infect Dis; 2013 Apr; 15(2):134-41. PubMed ID: 23173772
[TBL] [Abstract][Full Text] [Related]
15. Postoperative antimicrobials after lung transplantation and the development of multidrug-resistant bacterial and Clostridium difficile infections: an analysis of 500 non-cystic fibrosis lung transplant patients.
Whiddon AR; Dawson KL; Fuentes A; Perez KK; Peterson LE; Kaleekal T
Clin Transplant; 2016 Jul; 30(7):767-73. PubMed ID: 27091109
[TBL] [Abstract][Full Text] [Related]
16. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients.
Cusini A; Béguelin C; Stampf S; Boggian K; Garzoni C; Koller M; Manuel O; Meylan P; Mueller NJ; Hirsch HH; Weisser M; Berger C; van Delden C;
Am J Transplant; 2018 Jul; 18(7):1745-1754. PubMed ID: 29349869
[TBL] [Abstract][Full Text] [Related]
17. Hospital-onset Clostridium difficile infection among solid organ transplant recipients.
Donnelly JP; Wang HE; Locke JE; Mannon RB; Safford MM; Baddley JW
Am J Transplant; 2015 Nov; 15(11):2970-7. PubMed ID: 26484839
[TBL] [Abstract][Full Text] [Related]
18. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study.
Blumberg EA; Collins G; Young JH; Nguyen MH; Michonneau D; Temesgen Z; Origȕen J; Barcan L; Obeid KM; Belloso WH; Gras J; Corbelli GM; Neaton JD; Lundgren J; Snydman DR; Molina JM;
Transpl Infect Dis; 2022 Feb; 24(1):e13770. PubMed ID: 34821423
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center.
Tsapepas DS; Martin ST; Miao J; Shah SA; Scheffert J; Fester K; Ma K; Lat A; Egan R; McKeen JT
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):299-304. PubMed ID: 25586932
[TBL] [Abstract][Full Text] [Related]
20. Impact of oral vancomycin treatment duration on rate of
Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
